CD33 and acute myeloid leukemia: Due to the reduced potential of the CD33-CAR-T cells from AML patients and, in no less measure, the fact that delaying treatment in patients with AML may be unacceptable, we decided to approach these issues by generating allogeneic CD33-CAR-T cells.